Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 4/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 12/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5430020 | 0.87 | MEN1 (0.44) | HCRTR2HCRTR1MEN1KMT2ARIPK1 | |
| SCHEMBL5430005 | 0.84 | MEN1 (0.40) | HCRTR2HCRTR1MEN1KMT2ACCR5 | |
| SCHEMBL5420625 | 0.83 | MEN1 (0.40) | HCRTR2HCRTR1MEN1KMT2ACCR5 | |
| SCHEMBL5425021 | 0.82 | NR3C1 (0.45) | KMT2ACYP3A4CYP2D6 | |
| SCHEMBL5423453 | 0.82 | NR3C1 (0.39) | HCRTR2HCRTR1MEN1KMT2ARIPK1 | |
| SCHEMBL5427290 | 0.82 | LMNA (0.50) | MEN1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL5429847 | 0.81 | LIPE (0.43) | HCRTR2HCRTR1MEN1KMT2ARIPK1 | |
| SCHEMBL5431833 | 0.81 | HCRTR2 (0.47) | HCRTR2HCRTR1MEN1KMT2ARIPK1 | |
| SCHEMBL5701282 | 0.80 | HCRTR2 (0.39) | HCRTR2HCRTR1MEN1KMT2ACCR5 | |
| SCHEMBL5428771 | 0.80 | NR3C1 (0.39) | HCRTR2HCRTR1MEN1KMT2ARIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275990-A1 | Heterocyclic Spiro Compound | ONO PHARMACEUTICAL CO., LTD. | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275990-A1 | Heterocyclic Spiro Compound | NR3C2, CBR1, CBR3 | HCRTR2 968/4885HCRTR1 405/4885MEN1 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.